Medical technology firm Gamida Cell has raised $ 500 m in funding for its late - stage stem cell blood cancer therapy product , the cure . The product is currently undergoing phase 3 trials and is designed to allow bone marrow transplants for patients without a suitable bone marrow donor . The funding round was led by Shavit Capital and involved pharmaceutical company Novartis , which owns more than a 15 % stake in the company .
Medical technology firm Gamida Cell has gained $40m in funding for its late-stage stem cell blood cancer therapy treatment, the NiCord. The product is currently undergoing phase 3 trials and is designed to allow bone marrow transplants for patients without a suitable bone marrow donor. The funding round was led by Shavit Capital and involved pharmaceutical company Novartis, which owns more than a 15% stake in the firm.